Marvin M. Goldenberg
Marvin M. Goldenberg publishes mostly in Organic Chemistry, Molecular Biology and Pharmacology, on topics such as Synthesis and biological activity, Inflammatory mediators and NSAID effects and Neuropeptides and Animal Physiology.
- World rank
- #1,861,498 of 7,710,434 ranked researchers
- Rank in United States
- #569,959 of 1,627,098
- Works
- 84
- Citations
- 3.9k
- Citations per work
- 46.7
What does Marvin M. Goldenberg research?
Marvin M. Goldenberg's work is mostly in Chemistry (18%), Medicine (17%), Biochemistry, Genetics and Molecular Biology (10%).
Their six largest subfields, inside their fields and domains; the grey slice is everything else they publish. The interactive view splits every one of their works down to single topics.
The fields and subfields, with their numbers
- Everything else4351.1%
- Physical Sciences1517.7%
- Chemistry1517.7%
- Health Sciences1416.9%
- Medicine1416.9%
- Life Sciences1214.3%
- 1Organic Chemistry18% of their works
- 2Molecular Biology10% of their works
- 3Pharmacology6% of their works
- 4Surgery6% of their works
- 5Cellular and Molecular Neuroscience5% of their works
- 6Physiology4% of their works
Research topics
- Synthesis and biological activity
- Inflammatory mediators and NSAID effects
- Neuropeptides and Animal Physiology
- Helicobacter pylori-related gastroenterology studies
- Phenothiazines and Benzothiazines Synthesis and Activities
- Synthesis and Biological Evaluation
- Synthesis and Reactions of Organic Compounds
- Gastrointestinal motility and disorders
Which keywords describe Marvin M. Goldenberg's research?
The keywords of their largest research topics: Inflammation, Heterocyclic Compounds, Medicinal Chemistry, Synthesis, Tubulin Inhibitors, Vascular Targeting Agents, Cancer and Catalyst.
- Irritable Bowel Syndrome
- Gastrointestinal Disorders
- Phenothiazines
- Antimicrobial Activity
- Neuropeptides
- Gastric Cancer
- Catalyst
- Vascular Targeting Agents
- Synthesis
- Heterocyclic Compounds
- Inflammation
- Medicinal Chemistry
- Tubulin Inhibitors
- Cancer
- Cyclooxygenase-2 Inhibitors
- Helicobacter pylori
- Receptors
- Biological Activities
- Quinoxaline
- Imidazoles
- Oxazolones
Size is their works in the topics tagged with each word, from their 8 largest topics. Each links to the topic it comes from most. The words come from the keyword list OpenAlex gives each topic, not from the text of the papers, so a word can appear that none of the papers uses.
All 21 words, with their numbers
- Inflammation193 topics
- Heterocyclic Compounds152 topics
- Medicinal Chemistry152 topics
- Synthesis143 topics
- Tubulin Inhibitors101 topic
- Vascular Targeting Agents101 topic
- Cancer91 topic
- Catalyst92 topics
- Cyclooxygenase-2 Inhibitors91 topic
- Gastric Cancer61 topic
- Helicobacter pylori61 topic
- Neuropeptides61 topic
- Receptors61 topic
- Antimicrobial Activity51 topic
- Biological Activities51 topic
- Phenothiazines51 topic
- Quinoxaline51 topic
- Gastrointestinal Disorders41 topic
- Imidazoles41 topic
- Irritable Bowel Syndrome41 topic
- Oxazolones41 topic
Where does Marvin M. Goldenberg work?
Marvin M. Goldenberg's main affiliation in the publication record is Norwich University, United States.
How many publications and citations does Marvin M. Goldenberg have?
OpenAlex counts 84 works and 3,925 citations for Marvin M. Goldenberg, an h-index of 23, ranking #1,861,498 of 7,710,434 researchers worldwide on the quality score.
Ranked on field-normalised citation excellence (50%), output (30%) and citations (20%). Counts come from OpenAlex author records, which occasionally merge different people who share a name or split one person into several.
Papers, co-authors, who cited this work and researchers on the nearest topics have tabs of their own, above. Is this your page? Claim it with your ORCID iD, or request a correction or removal.
Discussion
Ask a question or share a note about Marvin M. Goldenberg. Keep it to the research: no personal attacks, advertising or links. Any reader can report a post, which collapses it for everyone until it is opened.